- Published: September 2, 2022
- Updated: September 2, 2022
- University / College: Brigham Young University
- Language: English
- Downloads: 37
In this particular case that is concerned with the development of a drug that will combat river blindness, a widespread disease among third world countries, it can be said that the primary stakeholders are composed of the employees of the Merck Company headed by John J. Horan. Merck’s chief executive, and Dr. P. Roy Vagelos, head of the Merck Sharp & Dohme Research Laboratories, and Dr. William Campbell, head of the Ivermectin research team of the Parasitological department (Bollier, 1991).
Secondary stakeholders, on the other hand, are composed of the victims of river blindness disease which are located in over 35 million developing countries all over the Third World (Bollier, 1991). The primary stakeholders are selected because they are considered to be the ones with direct influence and are holding the final decision regarding the progress of the development of the anti-Onchocerca volvulus drugs while the secondary stakeholders are the ones who are considered to manifest direct benefits once the drug is successfully developed.
What are the interests of the stakeholders? A. ) When to they converge? B. )When do they conflict? By analysis, the primary stakeholders are interested with the production of a profitable drug that will further support the importance and affirm the integrity of Merck in the international scientific community while the secondary stakeholders are concerned on the development of an antibiotic that will control the rapid spread of river blindness.
It can be said that both of these stakeholders will converge on the idea of formulating a product that will address the publichealthconcern that is affected by river blindness or onchocerciasis as influenced by thephilosophyof Merck’s vision expressing that “ medicine is for the people” (Bollier, 1991, pg. 3).
Conflict, on the other hand, is seen as product of the profitability issues of formulating anti-river blindness drugs, an event that is deemed to alleviate human suffering in many third world countries but is unlikely to bring monetary gains for Merck & Company, Inc. Reference Bollier, D. (1991). Merck & Co. , Inc. (A). The Business Enterprise Trust. 9-991-0221. Retrieved 26 May 2010, from http://www. cgsd. rutgers. edu/Documents/Shafer/327/Merck%20Case. pdf.